How do you approach molecular testing in patients with gastro-esophageal cancers?  

Does HER2 or PD1/PDL1 positivity change first line treatment (i.e. preferential enrollment on clinical trials) or do such patients still receiving standard of care chemotherapy?



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice